These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 32276450)

  • 1. Epstein-Barr Virus-Induced Post-Transplant Lymphoproliferative Disorder of the Central Nervous System Successfully Treated with Chemo-immunotherapy.
    Inoue H; Rai S; Tanaka H; Espinoza JL; Komori-Inoue M; Kakutani H; Minamoto S; Kumode T; Nakayama S; Taniguchi Y; Morita Y; Okuda T; Tatsumi Y; Ashida T; Matsumura I
    Viruses; 2020 Apr; 12(4):. PubMed ID: 32276450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity in clinical course of EBV-associated lymphoproliferative disorder after allogeneic stem cell transplantation.
    Meyer SC; Medinger M; Halter JP; Baldomero H; Hirsch HH; Tzankov A; Dirnhofer S; Passweg JR; Tichelli A
    Hematology; 2014 Jul; 19(5):280-5. PubMed ID: 24074746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A; Prete A; Belotti T; Gibertoni D; Piccirilli G; Gabrielli L; Pession A; Lazzarotto T
    Transpl Infect Dis; 2016 Feb; 18(1):44-54. PubMed ID: 26574232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of Rituximab-resistant Epstein-Barr virus-associated post-transplant lymphoproliferative disorder using R-CHOP.
    Kuriyama T; Kawano N; Yamashita K; Ueda A
    J Clin Exp Hematop; 2014; 54(2):149-53. PubMed ID: 25318948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Epstein-Barr virus with regression after withdrawal of immunosuppressive drugs and subsequent progression of iatrogenic immunodeficiency-associated lymphoproliferative disorders in patients with autoimmune diseases.
    Fujimoto K; Hatanaka KC; Hatanaka Y; Kasahara I; Yamamoto S; Tsuji T; Nakata M; Takakuwa Y; Haseyama Y; Oyamada Y; Yonezumi M; Suzuki H; Sakai H; Noguchi H; Mori A; Nishihara H; Teshima T; Matsuno Y
    Hematol Oncol; 2020 Dec; 38(5):799-807. PubMed ID: 32798315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation.
    Ru Y; Chen J; Wu D
    Eur J Haematol; 2018 Sep; 101(3):283-290. PubMed ID: 29949208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Manifestations of fulminant CD8 T-cell post-transplant lymphoproliferative disorder following the administration of rituximab for lymphadenopathy with a high level of Epstein-Barr Virus (EBV) replication after allogeneic hematopoietic stem cell transplantation.
    Tanaka T; Takizawa J; Miyakoshi S; Kozakai T; Fuse K; Shibasaki Y; Moriyama M; Ohshima K; Toba K; Furukawa T; Sone H; Masuko M
    Intern Med; 2014; 53(18):2115-9. PubMed ID: 25224199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia.
    Muramatsu H; Takahashi Y; Shimoyama Y; Doisaki S; Nishio N; Ito Y; Hama A; Shimada A; Yagasaki H; Ito M; Kojima S
    Int J Hematol; 2011 Jun; 93(6):779-781. PubMed ID: 21559814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-uniform
    Burns DM; Ryan GB; Harvey CM; Nagy E; Hughes S; Murray PG; Russell NH; Fox CP; Long HM
    Front Immunol; 2019; 10():2489. PubMed ID: 31736946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome of Epstein-Barr virus DNAemia and PTLD with the use of preemptive rituximab following allogeneic HSCT.
    Kinch A; Hallböök H; Arvidson J; Sällström K; Bondeson K; Pauksens K
    Leuk Lymphoma; 2018 May; 59(5):1172-1179. PubMed ID: 28831836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder.
    Czyzewski K; Styczynski J; Krenska A; Debski R; Zajac-Spychala O; Wachowiak J; Wysocki M
    Leuk Lymphoma; 2013 Mar; 54(3):503-6. PubMed ID: 22873830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful preemptive therapy with single-dose rituximab for Epstein-Barr virus infection to prevent post-transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation.
    Kim BK; Kang HJ; Hong KT; An HY; Choi JY; Lee JS; Park SS; Shin HY
    Transpl Infect Dis; 2019 Dec; 21(6):e13182. PubMed ID: 31556214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
    Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical Analysis of Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation in Severe Aplastic Anemia Patients].
    Yan HM; Zheng XL; Zhu L; Ding L; Han DM; Liu J; Xue M; Li S; Wang HX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1224-1229. PubMed ID: 35981389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation.
    Kalra A; Roessner C; Jupp J; Williamson T; Tellier R; Chaudhry A; Khan F; Taparia M; Jimenez-Zepeda VH; Stewart DA; Daly A; Storek J
    Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29114932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of Rituximab-Based Treatment for Post-Transplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience.
    Zhu CY; Zhao SS; Wang XK; Wang L; Wang FY; Fang S; Liu ZX; Guan LX; Liu YC; Ding Y; Dou LP; Wang LL; Gao CJ
    Ann Transplant; 2019 Apr; 24():175-184. PubMed ID: 30940797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr virus-associated post-transplant lymphoproliferative disease with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation.
    Nozzoli C; Bartolozzi B; Guidi S; Orsi A; Vannucchi AM; Leoni F; Bosi A
    Leuk Lymphoma; 2006 Jan; 47(1):167-9. PubMed ID: 16321845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of quantitative EBV DNA measurements in cerebrospinal fluid for diagnosis and monitoring of treatment of central nervous system EBV-associated post-transplant lymphoproliferative disorder after allogenic hematopoietic stem cell transplantation.
    Bocian J; Januszkiewicz-Lewandowska D
    Ann Transplant; 2014 May; 19():253-6. PubMed ID: 24866354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retransplantation after post transplant lymphoproliferative disorder: overcoming the obstacles!
    Prasad P; Khullar D; Gupta N; Grover R; Chhabra G; Gandhi KR; Gupta S; Bagai S
    CEN Case Rep; 2020 Aug; 9(3):200-203. PubMed ID: 32016786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus-related post-transplant lymphoproliferative disorder occurring after bone marrow transplantation for aplastic anemia in Down's syndrome.
    Furuya A; Ishida M; Hodohara K; Yoshii M; Okuno H; Horinouchi A; Nakanishi R; Harada A; Iwai M; Yoshida K; Kagotani A; Yoshida T; Okabe H
    Int J Clin Exp Pathol; 2014; 7(1):438-42. PubMed ID: 24427369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.